Home Alzheimer’s Disease High Starting Dose of Lenvatinib May Improve HR-QoL Among Patients with RCC

High Starting Dose of Lenvatinib May Improve HR-QoL Among Patients with RCC

According to a poster presented at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium, a higher starting dose of lenvatinib (Lenvima) improved health-related quality of life and led to longer time to deterioration compared with a lower starting dose of lenvatinib in patients with renal cell carcinoma (RCC).

“Based on these findings, patients who received lenvatinib 18 mg starting dose had better quality of life and less severe symptoms than those who received lenvatinib 14 mg starting dose,” said Cristiane Decat Bergerot, PhD, MS, BS, a postdoctoral fellow at City of Hope National Medical Center in Duarte, California, during the virtual poster presentation. “In addition, participants who received lenvatinib 18 mg maintained quality of life and symptom control for longer than those who received lenvatinib 14 mg starting dose.”

In this phase 2,…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Recent Comments